ANTI-TAC THERAPY FOR UVEITIS
| Status: | Completed |
|---|---|
| Conditions: | Cervical Cancer, Ocular |
| Therapuetic Areas: | Oncology, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 1996 |
| End Date: | September 2007 |
Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy
Uveitis refers to intraocular inflammatory diseases that are an important cause of visual
loss. Standard systemic immunosuppressive medications for uveitis can cause significant
adverse effects. Consequently, an effective treatment with a safer side effect profile is
highly desirable.
This pilot study has permitted enrollment of up to 12 adults with non-infectious
intermediate or posterior uveitis who require treatments to maintain visual function. This
extended protocol began with an evaluation of the safety and potential efficacy of
intravenous (IV) daclizumab treatments for uveitis while reducing or eliminating standard
medications commensurate with the standard of care. As subcutaneous (SC) daclizumab
treatments become available, eligible participants will be offered continuing daclizumab
treatments using the new SC formulation, though they may elect to remain on the IV
treatments. If the therapeutic benefit is sustained using the SC formulation, maintenance
therapy will continue as clinically indicated. Participants who repeatedly fail the SC
therapy will be permitted to revert to the IV daclizumab regimen they previously used, or
may exit the study as treatment failures. SC treatments begin with a short SC induction at 2
mg/kg followed by 1 mg/kg treatments on a 4-week schedule as the protocol originally
specified. Participants will be monitored routinely when each dose is received and
additionally will participate in pharmacokinetic studies to monitor SC formulation
bioavailability.
Daclizumab is a humanized anti-Tac monoclonal antibody (HAT, Zenapax) that interferes with
inflammatory processes by its involvement with the interleukin 2 receptor (IL-2R). During
the first 5 years of this study, only an IV product was available. The SC formulation is now
available containing the same daclizumab drug product. Preliminary studies indicate that the
SC formulation is well tolerated by normal control subjects and other autoimmune disease
patients at repeated doses up to 2 mg/kg.
The primary objectives are to examine the safety and potential efficacy of IV and later, SC
daclizumab, while continuing to reduce other immunosuppressive medications commensurate with
the standard of care. Primary safety outcomes are the discontinuation of study therapy due
to reduced vision or the occurrence of adverse events. Secondary outcome measures include
visual acuity and the grading of immunosuppressive medications, anterior chamber and
vitreous cells, and vitreous haze.
loss. Standard systemic immunosuppressive medications for uveitis can cause significant
adverse effects. Consequently, an effective treatment with a safer side effect profile is
highly desirable.
This pilot study has permitted enrollment of up to 12 adults with non-infectious
intermediate or posterior uveitis who require treatments to maintain visual function. This
extended protocol began with an evaluation of the safety and potential efficacy of
intravenous (IV) daclizumab treatments for uveitis while reducing or eliminating standard
medications commensurate with the standard of care. As subcutaneous (SC) daclizumab
treatments become available, eligible participants will be offered continuing daclizumab
treatments using the new SC formulation, though they may elect to remain on the IV
treatments. If the therapeutic benefit is sustained using the SC formulation, maintenance
therapy will continue as clinically indicated. Participants who repeatedly fail the SC
therapy will be permitted to revert to the IV daclizumab regimen they previously used, or
may exit the study as treatment failures. SC treatments begin with a short SC induction at 2
mg/kg followed by 1 mg/kg treatments on a 4-week schedule as the protocol originally
specified. Participants will be monitored routinely when each dose is received and
additionally will participate in pharmacokinetic studies to monitor SC formulation
bioavailability.
Daclizumab is a humanized anti-Tac monoclonal antibody (HAT, Zenapax) that interferes with
inflammatory processes by its involvement with the interleukin 2 receptor (IL-2R). During
the first 5 years of this study, only an IV product was available. The SC formulation is now
available containing the same daclizumab drug product. Preliminary studies indicate that the
SC formulation is well tolerated by normal control subjects and other autoimmune disease
patients at repeated doses up to 2 mg/kg.
The primary objectives are to examine the safety and potential efficacy of IV and later, SC
daclizumab, while continuing to reduce other immunosuppressive medications commensurate with
the standard of care. Primary safety outcomes are the discontinuation of study therapy due
to reduced vision or the occurrence of adverse events. Secondary outcome measures include
visual acuity and the grading of immunosuppressive medications, anterior chamber and
vitreous cells, and vitreous haze.
Uveitis refers to intraocular inflammatory diseases that are an important cause of visual
loss. Standard systemic immunosuppressive medications for uveitis can cause significant
adverse effects. Consequently, an effective treatment with a safer side effect profile is
highly desirable.
This pilot study has permitted enrollment of up to 12 adults with non-infectious
intermediate or posterior uveitis who require treatments to maintain visual function. This
extended protocol began with an evaluation of the safety and potential efficacy of
intravenous (IV) daclizumab treatments for uveitis while reducing or eliminating standard
medications commensurate with the standard of care. As subcutaneous (SC) daclizumab
treatments become available, eligible participants will be offered continuing daclizumab
treatments using the new SC formulation, though they may elect to remain on the IV
treatments. If the therapeutic benefit is sustained using the SC formulation, maintenance
therapy will continue as clinically indicated. Participants who repeatedly fail the SC
therapy will be permitted to revert to the IV daclizumab regimen they previously used, or
may exit the study as treatment failures. SC treatments begin with a short SC induction at 2
mg/kg followed by 1 mg/kg treatments on a 4-week schedule as the protocol originally
specified. Participants will be monitored routinely when each dose is received and
additionally will participate in pharmacokinetic studies to monitor SC formulation
bioavailability.
Daclizumab is a humanized anti-Tac monoclonal antibody (HAT, Zenapax) that interferes with
inflammatory processes by its involvement with the interleukin 2 receptor (IL-2R). During
the first 5 years of this study, only an IV product was available. The SC formulation is now
available containing the same daclizumab drug product. Preliminary studies indicate that the
SC formulation is well tolerated by normal control subjects and other autoimmune disease
patients at repeated doses up to 2 mg/kg.
The primary objectives are to examine the safety and potential efficacy of IV and later, SC
daclizumab, while continuing to reduce other immunosuppressive medications commensurate with
the standard of care. Primary safety outcomes are the discontinuation of study therapy due
to reduced vision or the occurrence of adverse events. Secondary outcome measures include
visual acuity and the grading of immunosuppressive medications, anterior chamber and
vitreous cells, and vitreous haze.
loss. Standard systemic immunosuppressive medications for uveitis can cause significant
adverse effects. Consequently, an effective treatment with a safer side effect profile is
highly desirable.
This pilot study has permitted enrollment of up to 12 adults with non-infectious
intermediate or posterior uveitis who require treatments to maintain visual function. This
extended protocol began with an evaluation of the safety and potential efficacy of
intravenous (IV) daclizumab treatments for uveitis while reducing or eliminating standard
medications commensurate with the standard of care. As subcutaneous (SC) daclizumab
treatments become available, eligible participants will be offered continuing daclizumab
treatments using the new SC formulation, though they may elect to remain on the IV
treatments. If the therapeutic benefit is sustained using the SC formulation, maintenance
therapy will continue as clinically indicated. Participants who repeatedly fail the SC
therapy will be permitted to revert to the IV daclizumab regimen they previously used, or
may exit the study as treatment failures. SC treatments begin with a short SC induction at 2
mg/kg followed by 1 mg/kg treatments on a 4-week schedule as the protocol originally
specified. Participants will be monitored routinely when each dose is received and
additionally will participate in pharmacokinetic studies to monitor SC formulation
bioavailability.
Daclizumab is a humanized anti-Tac monoclonal antibody (HAT, Zenapax) that interferes with
inflammatory processes by its involvement with the interleukin 2 receptor (IL-2R). During
the first 5 years of this study, only an IV product was available. The SC formulation is now
available containing the same daclizumab drug product. Preliminary studies indicate that the
SC formulation is well tolerated by normal control subjects and other autoimmune disease
patients at repeated doses up to 2 mg/kg.
The primary objectives are to examine the safety and potential efficacy of IV and later, SC
daclizumab, while continuing to reduce other immunosuppressive medications commensurate with
the standard of care. Primary safety outcomes are the discontinuation of study therapy due
to reduced vision or the occurrence of adverse events. Secondary outcome measures include
visual acuity and the grading of immunosuppressive medications, anterior chamber and
vitreous cells, and vitreous haze.
- INCLUSION CRITERIA
Participant is 18 years of age or older.
Participant has a diagnosis of sight-threatening, intermediate or posterior uveitis of at
least three months duration prior to orginal enrollment, requiring treatment to control
their intraocular inflammatory disease with at least 20 mg/day of prednisone (or
equivalent) or any combination of two or more anti-inflammatory treatments for uveitis,
including for example prednisone, cyclophosphamide, cyclosporine, azathioprine,
mycophenolate mofetil, methotrexate, etc.
Participant exhibits intolerance to the indicated systemic medications required for their
uveitis or, though their uveitis may be under control, wish to be taken off their present
medications due to potential or actual unacceptable side effects.
Participant has visual acuity in at least one eye of 20/63 or better (ETDRS, logMAR less
than 0.54).
Participant has normal renal or liver function or evidence of no worse than mild
abnormalities as defined by the WHO/NEI criteria.
Participant is not currently pregnant or lactating.
Participant with reproductive potential and who is sexually active agrees to use
acceptable birth control methods throughout the course of the study.
EXCLUSION CRITERIA
Participants under the age of 18 years.
Participants who had received previous treatment with an IL-2 directed monoclonal antibody
or any other investigational agent that would interfere with the ability to evaluate the
safety, efficacy or pharmacokinetics of daclizumab.
Participants with a history or diagnosis of Behcet's disease.
Participant has a significant active infection.
Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed
within the past 5 years.
Participant is hypersensitive to fluorescein dye.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
